Cure8 regulatory brief
This project describes a novel off-the-shelf engineered regulatory T cell therapy aiming to promote intestinal immune regulation and mucosal healing — a different approach than current biologics. If successful, it could offer a new treatment option for people who don’t reach durable remission with existing drugs.
Patients with moderate-to-severe IBD or those who have failed existing biologics, clinicians following emerging cell therapies, and researchers in cell therapy, immunology, and IBD translational science.
NIH Reporter lists a funded GentiBio project developing GNTI-932, an allogeneic engineered regulatory T cell (EngTreg) therapy designed to be gut-localizing and hypoimmune for treatment of IBD (Crohn’s disease and ulcerative colitis).
The program combines FOXP3 overexpression for a stable Treg phenotype, a chemically inducible IL-2 signaling system, and immune-evasion edits (HLA knockdown and NK inhibition) with BTNL3/8-based gut targeting.
The entry describes planned preclinical validation using in vivo studies and patient-derived intestinal organoids to assess functionality, safety, persistence, and barrier-repair activity. The project record frames GNTI-932 as an off-the-shelf cell therapy intended to overcome durability, tissue specificity, and persistence limits of prior Treg approaches.
The description focuses on mechanism and preclinical development rather than clinical results; it does not report patient outcomes or trial data.
This is a funded research project record (project-level summary) describing an investigational, preclinical-to-industry-stage cell therapy approach; it does not represent an approved treatment and should not be interpreted as demonstrating safety or efficacy in humans.
This record is a funded project abstract on NIH Reporter describing preclinical development and planned validation work. It does not provide clinical-trial results; the therapy remains investigational and requires human testing and regulatory review before clinical availability.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: National Institute of Diabetes and Digestive and Kidney Diseases - R44DK148134 - $1,061,227
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Early clinical data suggest PALI-2108 may affect both inflammation and fibrosis in Crohn’s disease and shows biomarker changes (like fecal calprotectin) that could matter to people monitoring disease activity.
This project could introduce a novel, microbiome-targeted oral therapy for Crohn’s disease if the Phase II trial confirms safety and clinical benefit; that matters because many patients need new options when current...
This narrative review surveys novel biomarkers and therapeutic strategies for adult IBD, topics that could affect diagnosis, monitoring, and future treatment options for people with Crohn's disease or ulcerative colitis.
